Evidence map›Paper›PMID 36903800›Full record

ArticleNanomaterials (Basel, Switzerland)2023

Nanomaterial Characterization in Complex Media-Guidance and Application.

Yves Uwe Hachenberger, Daniel Rosenkranz, Charlotte Kromer, Benjamin Christoph Krause, Nadine Dreiack, Fabian Lukas Kriegel, Ekaterina Koz'menko, Harald Jungnickel, Jutta Tentschert, Frank Stefan Bierkandt and 3 more

Full text read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yves Uwe HachenbergerDepartment of Chemical & Product Safety, German Federal Institute for Risk Assessment (BfR), Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany.ORCID 0000-0002-0727-5053
Daniel RosenkranzInstitute for Clinical Chemistry and Laboratory Medicin, Klinikum Oldenburg AöR, Rahel-Straus-Straße 10, 26133 Oldenburg, Germany.ORCID 0000-0002-5978-4685
Charlotte KromerDepartment of Chemical & Product Safety, German Federal Institute for Risk Assessment (BfR), Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany.ORCID 0000-0003-4823-4714
Benjamin Christoph KrauseDepartment of Chemical & Product Safety, German Federal Institute for Risk Assessment (BfR), Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany.ORCID 0000-0003-4684-2206
Nadine DreiackDepartment of Chemical & Product Safety, German Federal Institute for Risk Assessment (BfR), Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany.ORCID 0000-0001-7637-0284
Fabian Lukas KriegelDepartment of Chemical & Product Safety, German Federal Institute for Risk Assessment (BfR), Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany.ORCID 0000-0003-1536-2840
Ekaterina Koz'menkoDepartment of Chemical & Product Safety, German Federal Institute for Risk Assessment (BfR), Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany.
Harald JungnickelDepartment of Chemical & Product Safety, German Federal Institute for Risk Assessment (BfR), Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany.ORCID 0000-0002-1854-5354
Jutta TentschertDepartment of Chemical & Product Safety, German Federal Institute for Risk Assessment (BfR), Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany.ORCID 0000-0002-4603-7293
Frank Stefan BierkandtDepartment of Chemical & Product Safety, German Federal Institute for Risk Assessment (BfR), Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany.ORCID 0000-0002-3393-1536
Peter LauxDepartment of Chemical & Product Safety, German Federal Institute for Risk Assessment (BfR), Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany.ORCID 0000-0002-0351-3392
Ulrich PanneFederal Institute for Materials Research and Testing (BAM), Richard-Willstätter-Strasse 11, 12489 Berlin, Germany.ORCID 0000-0001-6044-4998
Andreas LuchDepartment of Chemical & Product Safety, German Federal Institute for Risk Assessment (BfR), Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany.ORCID 0000-0002-5866-901X

Funding

BfR-SFP 1322-723, 1322-724, 1322-642European Union 720952
6 · The paper itself

Abstract

A broad range of inorganic nanoparticles (NPs) and their dissolved ions possess a possible toxicological risk for human health and the environment. Reliable and robust measurements of dissolution effects may be influenced by the sample matrix, which challenges the analytical method of choice. In this study, CuO NPs were investigated in several dissolution experiments. Two analytical techniques (dynamic light scattering (DLS) and inductively-coupled plasma mass spectrometry (ICP-MS)) were used to characterize NPs (size distribution curves) time-dependently in different complex matrices (e.g., artificial lung lining fluids and cell culture media). The advantages and challenges of each analytical approach are evaluated and discussed. Additionally, a direct-injection single particle (DI sp)ICP-MS technique for assessing the size distribution curve of the dissolved particles was developed and evaluated. The DI technique provides a sensitive response even at low concentrations without any dilution of the complex sample matrix. These experiments were further enhanced with an automated data evaluation procedure to objectively distinguish between ionic and NP events. With this approach, a fast and reproducible determination of inorganic NPs and ionic backgrounds can be achieved. This study can serve as guidance when choosing the optimal analytical method for NP characterization and for the determination of the origin of an adverse effect in NP toxicity.

Indexed as

characterizationdissolutionmatrixnanospICP-MS

Identifiers

PMID36903800
PMCPMC10005142

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read26
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.